Accueil   Diary - News   All news Alizé Pharma acquires exclusive worldwide rights on a new peptide

Alizé Pharma acquires exclusive worldwide rights on a new peptide

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.


The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro and in vivo studies showed the peptides’ ability to induce bone formation by stimulating osteoblast differentiation and inhibiting osteoclast differentiation.

 

Read the press release